Studying a new drug for cancers with a specific TP53 change
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (or 12–17 with special approval).
- Your cancer is advanced or has spread and has the TP53 Y220C change.
- You have tried at least one prior cancer treatment, and your cancer has grown.
- You are able to do daily activities (ECOG 0 or 1).
- You have at least one tumor that can be measured on scans.
- You have adequate organ function (kidneys, liver, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a new drug called LG00313112 in people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug is designed to target tumors with this mutation, and the study aims to see if it can help shrink or control the cancer.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests a personalized cell therapy that uses your own immune cells, modified to target a specific genetic mutation found in some tumors. It aims to see if this treatment can shrink tumors or slow their growth in people with advanced cancer.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.